Biognosis buys Abion to serve as research & development centre:
This article was originally published in Clinica
Biognosis has bought the assets of Abion, of Julich, Germany, and formed a new German subsidiary, Biognosis. The UK company, which is developing serology tests for infectious diseases, says Abion's technology supports its development of high speed, quantitative immunoassays. The German subsidiary will serve as Biognosis' R&D centre. High Wycombe-based Biognosis, which is privately-funded, plans to spend DM10 million ($5.6 million) on development projects over the next four years. The first are expected in mid-1999.
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.